As part of the multi-part series on Natural Killer Cell Therapies, this week on the podcast, Agustin discusses $AFMD. He explains the  company's technology, pipeline, and recent catalysts. Additionally, he addresses some key questions including the monotherapy potential of AFM13 and AFM24 and where Affimed stands relative to other companies within the NK cell therapy space.  

Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros 

All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com